-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There is growing evidence that liver fibrosis or cirrhosis associated with hepatitis B virus (HBV) can subside in histology if HBV replication is inhibited.
, however, it is worth noting that liver fibrosis still occurs in 10 to 20 per cent of patients, despite effective antiviral treatment.
therefore, identifying risk factors associated with the progression of fibrosis is of clinical importance, and this study aims to identify risk factors for the progression of fibrosis in patients receiving antiviral therapy.
researchers conducted a longitudinal study of 78 patients with parallel liver biopsies of chronic HBV infection treated with anti-HBV.
fibrosis is defined as an increase in the isak phase≥1 or is confirmed primarily by classification through the PIR system.
HBV DNA and HBV RNA levels in blood samples with real-time quantitative PCR.
to detect HBV RNA in liver tissue through in-place hybridization.
study included a total of 239 liver biopsies of chronic HBV infection.
of the 163 patients with significant fibrosis at baseline (Ishak≥3), 22 (13%) developed fibrosis, 24 (15%) were uncertain about fibrosis, and 117 (72%) had liver fiber subsidence.
single-factor and multi-factor analysis showed that the independent risk factor for fibrosis progress was a higher rate of detection of HBV DNA at week 78 (OR:4.84; 95% CI: 1.30-17.98; P s .019) and alcohol intake (OR:23.84; 95% CI: 2.68-212.50; P s .004).
At the 78th week, the proportion of HBV DNA detected in blood samples from patients with fibrosis progression (50%) was significantly higher than in fibrosis recedence (19%) or in uncertain fibrosis patients (26%) (P-.015), although viralemia was low in all groups (20-200 IU/mL).
HBV RNA from the baseline in the serum fibrosis receding group was greater than in the fibrosis progress group.
this study confirms that progress in liver fibrosis in week 78 of treatment is associated with higher HBV DNA detection rates.
low levels of residual HBV may still promote the fibrosis process, patients' HBV DNA levels should be carefully monitored.
.
